Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2021 08:00 ET | Source: Genmab A/S

Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)

Media Release Copenhagen, Denmark, October 1, 2021 Mini-oral presentation highlighting data from first-in-human trial evaluating investigational bispecific antibody DuoBody®-CD40×4-1BB...
September 21, 2021 14:22 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The...
September 20, 2021 17:00 ET | Source: Genmab A/S

Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer CellsNew Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
September 19, 2021 11:30 ET | Source: Genmab A/S

Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021

Media Release Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment Tisotumab Vedotin in Combination with Pembrolizumab Showed...
September 09, 2021 07:00 ET | Source: Genmab A/S

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet

Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell...
August 27, 2021 04:42 ET | Source: Genmab A/S

Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Media ReleaseCopenhagen, Denmark, 27 August, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D. will participate in a virtual fireside chat at the Morgan Stanley...
August 17, 2021 14:51 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 17, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,370 shares as a consequence of the exercise of employee warrants. The...
August 11, 2021 11:01 ET | Source: Genmab A/S

Genmab Announces Financial Results for the First Half of 2021

August 11, 2021; Copenhagen, Denmark; Interim Report for the First Half of 2021 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application...
July 21, 2021 12:58 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
July 21, 2021 06:31 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021

Company Announcement Net sales of DARZALEX® in the second quarter of 2021 totaled USD 1,433 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...